Timber Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TMBR research report →
Price Chart
About the company
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials.
- CEO
- John Koconis
- IPO
- 2014
- Employees
- 9
- HQ
- Basking Ridge, NJ, US
Get TickerSpark's AI analysis on TMBR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.18M
- P/E
- -0.04
- PEG
- -0.00
- P/S
- 14.14
- P/B
- 0.14
- EV/EBITDA
- 0.40
- Div Yield
- 0.00%
- Gross Margin
- -15892.35%
- Op Margin
- -23125.86%
- Net Margin
- -23299.05%
- ROE
- -209.49%
- ROIC
- -345.61%
Latest fiscal year · YoY change
- Revenue
- $83.18K-71.9%
- Gross Profit
- $-13,218,781-125.8%
- Op Income
- $-19,235,396
- Net Income
- $-19,379,450-82.2%
- EPS
- $-9.19+30.1%
- OCF Growth
- -70.2%
- FCF Growth
- -70.0%
- 52W High
- $3.39
- 52W Low
- $0.32
- 50D MA
- $2.45
- 200D MA
- $2.12
- Beta
- -0.65
- RSI (14)
- 38
- Avg Volume
- 107.90K
No earnings-call transcripts are available for TMBR yet.
- Free Float
- 81.2%
- Shares Outstanding
- 3.43M
- Float Shares
- 2.79M
of shares held by institutions
10 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 20, 23 | Koconis John | other | 70,385 |
| Aug 20, 23 | Mendelsohn Alan | other | 35,193 |
| Aug 20, 23 | Lucchese Joseph | other | 35,193 |
| Apr 15, 23 | Koconis John | other | 45,010 |
| Apr 15, 23 | Gaal Lubor | other | 4,100 |
| Apr 15, 23 | Gaal Lubor | other | 4,100 |
| Apr 15, 23 | Mendelsohn Alan | other | 22,505 |
| Apr 15, 23 | Pirozzi Gianluca | other | 4,100 |
| Apr 15, 23 | Pirozzi Gianluca | other | 4,100 |
| Apr 15, 23 | Sitar Edward J | other | 5,327 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TMBR coverage
Recent articles, reports, and earnings notes.
No research on TMBR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TMBR report →MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources
nypost.com · Jan 31
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
businesswire.com · Mar 10
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
businesswire.com · Jan 23
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
prismmediawire.com · Nov 29
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
globenewswire.com · Nov 29
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
globenewswire.com · Nov 28
NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)
businesswire.com · Nov 21
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
globenewswire.com · Sep 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.